Table 2. Predicted biological impact of mutations in the SARS-CoV-2 501Y.V2 spike protein.
| SARS-CoV-2 501Y.V2 | ||
|---|---|---|
| Variation | PROVEAN | SIFT |
| Leu18Phe | Neutral | Tolerated |
| Asp80Ala | Neutral | Tolerated |
| Asp215Gly | Neutral | Tolerated |
| Leu242 Deletion | N/A | N/A |
| Leu242-244 Deletion | N/A | N/A |
| Arg246Ile | Neutral | Deleterious |
| Lys417Asn | Neutral | Tolerated |
| Glu484Lys | Neutral | Tolerated |
| Asn501Tyr* | Neutral | Tolerated |
| Asp614Gly* | Neutral | Tolerated |
| Ala701Val | Neutral | Tolerated |
Predicted effects of amino acid substitutions common in SARS-CoV-2 501Y.V2 using Protein Variation Effect Analyzer (PROVEAN) [46] and SIFT [47, 48]. Variants predicted to have a deleterious impact on spike protein are shaded red.
*Mutation common to both variants. N/A = not applicable as software does not make predictions about deletions.